课题基金 / 基金详情

Silicone Hydrogel Contact Lenses with Controlled and Extended Release of Latanopr

Silicone Hydrogel Contact Lenses with Controlled and Extended Release of Latanopr
具有可控和缓释 Latanopr 的硅水凝胶隐形眼镜
批准号:
8815180
负责人:
Mark E. Byrne
金额:
$14.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-03-01 至 2018-02-28

项目摘要

项目成果

Mark E. Byrne的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: The objective of this project is to develop a novel extended wear contact lens with controllable and sustained release of latanoprost for the duration of wear to treat glaucoma. Glaucoma is the second leading cause of blindness in the world with the total number of cases estimated at over 70 million worldwide. There is a substantial need for more efficacious and convenient delivery of ocular therapeutics, especially glaucoma medication, via non-invasive platforms. Current treatment options predominantly consist of topical eye drops, which lead to significant peaks and valleys in drug concentration and intraocular pressure (IOP). The proposed work aims to solve these problems as well as poor patient compliance with increased latanoprost bioavailability and decreased side effects leading to significantly better patient outcomes. Novel, silicone hydrogel lenses will be rationally designed and synthesized with significant control over latanoprost release and loading while maintaining conventional lens properties such as optical clarity, mechanical properties, and oxygen diffusivity. The structure of the lens will be engineered by varying composition and polymerization conditions to produce macromolecular memory for latanoprost via non-covalent interactions within the polymer lens, leading to strict control of delivery rate and loading. Polymer lens structural, mechanical, optica properties will be characterized as well as in vitro latanoprost release at physiological flow conditions that match tear flow rate and turnover in the eye. In vivo latanoprost release from engineered contact lenses will be evaluated and compared to topical administration in canines measuring IOP and ocular concentration versus time. It is expected that engineered lenses will lead to a constant rate of latanoprost release and lead to approximately constant concentrations of drug in the eye, with little to no peaks and valleys, and a constant decreased IOP for the duration of lens wear.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/opx.0000000000000849
发表时间: 2016-04
期刊: Optometry and vision science : official publication of the American Academy of Optometry
影响因子: --
作者: [White CJ, DiPasquale SA, Byrne ME]
通讯作者: Byrne ME
In vivo drug delivery via contact lenses: The current state of the field from origins to present.
通过隐形眼镜进行体内药物输送:该领域从起源到现在的现状。
DOI: 10.1016/j.jddst.2021.102413
发表时间: 2021
期刊: Journal of drug delivery science and technology
影响因子: 5
作者: [Wuchte,LianaD, DiPasquale,StephenA, Byrne,MarkE]
通讯作者: Byrne,MarkE
Silicone Hydrogel Contact Lenses with Controlled and Extended Release of Latanopr
  • 批准号:
    8638312
  • 项目类别:
  • 资助金额:
    $15.2万
  • 财政年份:
    2014
  • 负责人:
    Mark E. Byrne
  • 依托单位:
海外基金